What question did this study set out to answer?

To evaluate whether adjuvant interferon alfa-2b improves relapse-free interval and overall survival in patients with high-risk resected cutaneous melanoma.

January 1, 1996Journal of Clinical Oncology

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

View Full Paper

Ask AI

Bookmark

Authors

JKJ M KirkwoodUniversity of Pittsburgh Medical Center MSM H StrawdermanUniversity of Pittsburgh Medical Center MEMarc S. ErnstoffDartmouth Institute for Health Policy and Clinical Practice

Discussion

Member takes

Implication

Randomized controlled trial demonstrates prolonged relapse-free and overall survival with interferon alfa-2b in high-risk resected melanoma, highlighting its efficacy as an adjuvant therapy.

Key Points

To evaluate whether adjuvant interferon alfa-2b improves relapse-free interval and overall survival in patients with high-risk resected cutaneous melanoma.
Randomized controlled trial (Eastern Cooperative Oncology Group Trial EST 1684) comparing adjuvant interferon alfa-2b against observation.
Conducted in patients with high-risk, surgically resected cutaneous melanoma.
Interferon alfa-2b extended median disease-free survival from 1.0 to 1.7 years and median overall survival from 2.8 to 3.8 years compared with observation.
Treatment resulted in a 42% relative improvement in continuous disease-free survival, increasing the disease-free proportion from 26% with observation to 37% with interferon alfa-2b.

Cite This Study

Kirkwood et al. (1996) studied this question.

synapsesocial.com/papers/69d6bfdbfca0359822aa832b https://doi.org/10.1200/jco.1996.14.1.7

View Full Paper

Ask AI

Bookmark

Implication

Randomized controlled trial demonstrates prolonged relapse-free and overall survival with interferon alfa-2b in high-risk resected melanoma, highlighting its efficacy as an adjuvant therapy.

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Discussion

Member takes

Implication

Key Points

Cite This Study

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider